Skip to main content

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.

Publication ,  Journal Article
Sandhu, RK; Ezekowitz, JA; Hijazi, Z; Westerbergh, J; Aulin, J; Alexander, JH; Granger, CB; Halvorsen, S; Hanna, MS; Lopes, RD; Siegbahn, A ...
Published in: Open Heart
2018

OBJECTIVE: We investigated the association between obesity and biomarkers indicating cardiac or renal dysfunction or inflammation and their interaction with obesity and outcomes. METHODS: A total of 14 753 patients in the Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial provided plasma samples at randomisation to apixaban or warfarin. Median follow-up was 1.9 years. Body Mass Index (BMI) was measured at baseline and categorised as normal, 18.5-25  kg/m2; overweight, >25 to <30 kg/m2; and obese, ≥30 kg/m2. We analysed the biomarkers high-sensitivity C reactive protein (hs-CRP), interleukin 6 (IL-6), growth differentiation factor-15 (GDF-15), troponin T and N-terminal B-type natriuretic peptide (NT-pro-BNP). Outcomes included stroke/systemic embolism (SE), myocardial infarction (MI), composite (stroke/SE, MI, or all-cause mortality), all-cause and cardiac mortality, and major bleeding. RESULTS: Compared with normal BMI, obese patients had significantly higher levels of hs-CRP and IL-6 and lower levels of GDF-15, troponin T and NT-pro-BNP. In multivariable analyses, higher compared with normal BMI was associated with a lower risk of all-cause mortality (overweight: HR 0.73 (95% CI 0.63 to 0.86); obese: 0.67 (0.56 to 0.80), p<0.0001), cardiac death (overweight: HR 0.74 (95% CI 0.60 to 0.93); obese: 0.71 (0.56 to 0.92), p=0.01) and composite endpoint (overweight: 0.80 (0.70 to 0.92); obese: 0.72 (0.62 to 0.84), p<0.0001). CONCLUSIONS: Regardless of biomarkers indicating inflammation or cardiac or renal dysfunction, obesity was independently associated with an improved survival in anticoagulated patients with AF. TRIAL REGISTRATION NUMBER: NCT00412984.

Duke Scholars

Published In

Open Heart

DOI

ISSN

2053-3624

Publication Date

2018

Volume

5

Issue

2

Start / End Page

e000908

Location

England

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sandhu, R. K., Ezekowitz, J. A., Hijazi, Z., Westerbergh, J., Aulin, J., Alexander, J. H., … Wallentin, L. (2018). Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart, 5(2), e000908. https://doi.org/10.1136/openhrt-2018-000908
Sandhu, Roopinder K., Justin A. Ezekowitz, Ziad Hijazi, Johan Westerbergh, Julia Aulin, John H. Alexander, Christopher B. Granger, et al. “Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.Open Heart 5, no. 2 (2018): e000908. https://doi.org/10.1136/openhrt-2018-000908.
Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, et al. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018;5(2):e000908.
Sandhu, Roopinder K., et al. “Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.Open Heart, vol. 5, no. 2, 2018, p. e000908. Pubmed, doi:10.1136/openhrt-2018-000908.
Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018;5(2):e000908.

Published In

Open Heart

DOI

ISSN

2053-3624

Publication Date

2018

Volume

5

Issue

2

Start / End Page

e000908

Location

England

Related Subject Headings

  • 3201 Cardiovascular medicine and haematology